clofibric acid has been researched along with Coronary Artery Disease in 24 studies
Clofibric Acid: An antilipemic agent that is the biologically active metabolite of CLOFIBRATE.
clofibric acid : A monocarboxylic acid that is isobutyric acid substituted at position 2 by a p-chlorophenoxy group. It is a metabolite of the drug clofibrate.
Coronary Artery Disease: Pathological processes of CORONARY ARTERIES that may derive from a congenital abnormality, atherosclerotic, or non-atherosclerotic cause.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The study of the hypolipidemic efficiency, safety and tolerance of ciprofibrate (lipanor) in therapy of atherogenic hyperlipoproteinemia." | 5.08 | [Lipanor treatment of atherogenic hyperlipoproteinemia]. ( Arabidze, GG; Kukharchuk, VV; Susekov, AV; Tvorogova, MG, 1998) |
| "As the significance of treating coronary artery disease (CAD) remains a high priority in reducing morbidity and mortality worldwide, newer treatment strategies continue to evolve." | 2.45 | Novel targets that affect high-density lipoprotein metabolism: the next frontier. ( Davidson, MH; Rosenson, RS, 2009) |
| "Furthermore, severe hypertriglyceridemia is associated with an increased risk of acute pancreatitis, irrespective of its effect on risk of cardiovascular disease." | 2.44 | Hypertriglyceridemia: its etiology, effects and treatment. ( Al-Shali, KZ; Hegele, RA; Yuan, G, 2007) |
| "Niacin has been shown to regress atherosclerosis when used as monotherapy, in combination with a statin, and in combination with nonstatin therapies (including cholesterol-binding resins) and fibrates." | 2.44 | Evidence to support aggressive management of high-density lipoprotein cholesterol: implications of recent imaging trials. ( Taylor, AJ, 2008) |
| "Thus, targeting the hyperglycemia in type 2 diabetes mellitus (DM) alone will not eliminate all of the excess cardiovascular risk; rather aggressive treatment is needed for all of the modifiable cardiometabolic risk factors." | 2.44 | Type 2 diabetes mellitus is associated with multiple cardiometabolic risk factors. ( Gerich, JE, 2007) |
| "Furthermore, hypertriglyceridemia is now recognized as an independent risk factor for coronary artery disease." | 2.43 | Mode of action of fibrates in the regulation of triglyceride and HDL-cholesterol metabolism. ( Duriez, P; Fruchart, JC, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (12.50) | 18.2507 |
| 2000's | 20 (83.33) | 29.6817 |
| 2010's | 1 (4.17) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Tentolouris, N | 1 |
| Eleftheriadou, I | 1 |
| Katsilambros, N | 1 |
| Davidson, MH | 2 |
| Rosenson, RS | 1 |
| Pöss, J | 1 |
| Böhm, M | 1 |
| Laufs, U | 1 |
| Doggrell, SA | 1 |
| Wierzbicki, AS | 1 |
| Steiner, G | 1 |
| Candido, R | 1 |
| Zanetti, M | 1 |
| Schwiesow, SJ | 1 |
| Nappi, JM | 1 |
| Ragucci, KR | 1 |
| Klose, G | 1 |
| Fruchart, JC | 1 |
| Duriez, P | 1 |
| Espinosa, RA | 1 |
| Rodríguez-Roa, E | 1 |
| Nagy, E | 1 |
| Mijares, ME | 1 |
| Rodríguez-Larralde, A | 1 |
| Gil, A | 1 |
| Lundberg, U | 1 |
| Carvajal, Z | 1 |
| Castillo, L | 1 |
| Arocha-Piñango, CL | 1 |
| Rigotti R, A | 1 |
| Arteaga Ll, A | 1 |
| Maiz G, A | 1 |
| Yuan, G | 1 |
| Al-Shali, KZ | 1 |
| Hegele, RA | 1 |
| Sposito, AC | 1 |
| Caramelli, B | 1 |
| Fonseca, FA | 1 |
| Bertolami, MC | 1 |
| Afiune Neto, A | 1 |
| Souza, AD | 1 |
| Lottenberg, AM | 1 |
| Chacra, AP | 1 |
| Faludi, AA | 1 |
| Loures-Vale, AA | 1 |
| Carvalho, AC | 1 |
| Duncan, B | 1 |
| Gelonese, B | 1 |
| Polanczyk, C | 1 |
| Rodrigues Sobrinho, CR | 1 |
| Scherr, C | 1 |
| Karla, C | 1 |
| Armaganijan, D | 1 |
| Moriguchi, E | 1 |
| Saraiva, F | 1 |
| Pichetti, G | 1 |
| Xavier, HT | 1 |
| Chaves, H | 1 |
| Borges, JL | 1 |
| Diament, J | 1 |
| Guimarães, JI | 1 |
| Nicolau, JC | 1 |
| dos Santos, JE | 1 |
| de Lima, JJ | 1 |
| Vieira, JL | 1 |
| Novazzi, JP | 1 |
| Faria Neto, JR | 1 |
| Torres, KP | 1 |
| Pinto, Lde A | 1 |
| Bricarello, L | 1 |
| Bodanese, LC | 1 |
| Introcaso, L | 1 |
| Malachias, MV | 1 |
| Izar, MC | 1 |
| Magalhães, ME | 1 |
| Schmidt, MI | 1 |
| Scartezini, M | 1 |
| Nobre, M | 1 |
| Foppa, M | 1 |
| Forti, NA | 1 |
| Berwanger, O | 1 |
| Gebara, OC | 1 |
| Coelho, OR | 1 |
| Maranhão, RC | 1 |
| dos Santos Filho, RD | 1 |
| Costa, RP | 1 |
| Barreto, S | 1 |
| Kaiser, S | 1 |
| Ihara, S | 1 |
| Carvalho, Td | 1 |
| Martinez, TL | 1 |
| Relvas, WG | 1 |
| Salgado, W | 1 |
| Yavasoglu, I | 1 |
| Kadikoylu, G | 1 |
| Bolaman, Z | 1 |
| Röggla, G | 1 |
| Fasan, M | 1 |
| Kapiotis, S | 1 |
| Holub, BJ | 1 |
| Toth, PP | 1 |
| Taylor, AJ | 1 |
| Gerich, JE | 1 |
| Hausenloy, DJ | 1 |
| Yellon, DM | 1 |
| Anber, V | 2 |
| Millar, JS | 2 |
| McConnell, M | 1 |
| Shepherd, J | 2 |
| Packard, CJ | 2 |
| Susekov, AV | 1 |
| Tvorogova, MG | 1 |
| Arabidze, GG | 1 |
| Kukharchuk, VV | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Study to Assess the Consequences of Postprandial Lipemia in CRP as Inflammatory Marker in High-risk Adults, to Investigate Whether Hypolipidemic, Hypoglycemic or Antihypertensive Medication May Lessen the Exaggerated Postprandial Lipemia and Evaluate th[NCT02163044] | 580 participants (Actual) | Observational | 2014-09-30 | Completed | |||
| Effect of Nutritional Intervention and Olive Oil in Severe Obesity: Randomized Controlled Trial[NCT02463435] | 229 participants (Actual) | Interventional | 2015-06-30 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
14 reviews available for clofibric acid and Coronary Artery Disease
| Article | Year |
|---|---|
The effects of medications used for the management of dyslipidemia on postprandial lipemia.
Topics: Apolipoproteins B; Cholesterol Ester Transfer Proteins; Chylomicrons; Clofibric Acid; Coronary Arter | 2009 |
Novel targets that affect high-density lipoprotein metabolism: the next frontier.
Topics: Apolipoprotein A-I; Cholesterol Ester Transfer Proteins; Cholesterol, HDL; Clinical Trials as Topic; | 2009 |
[HDL and CETP in atherogenesis].
Topics: Amides; Anticholesteremic Agents; Atherosclerosis; Cholesterol Ester Transfer Proteins; Cholesterol, | 2010 |
Raising high-density lipoprotein cholesterol with inhibitors of cholesteryl ester transfer protein - a new approach to coronary artery disease.
Topics: Carrier Proteins; Cholesterol Ester Transfer Proteins; Cholesterol, HDL; Cholesterol, LDL; Clinical | 2004 |
Have we forgotten the pivotal role of high-density lipoprotein cholesterol in atherosclerosis prevention?
Topics: Arteriosclerosis; Cholesterol, HDL; Clofibric Acid; Coronary Artery Disease; Disease Progression; Hu | 2005 |
Fibrates and coronary risk reduction.
Topics: Cholinergic Antagonists; Clofibric Acid; Coronary Artery Disease; Humans; Risk Factors | 2005 |
Current perspective. Diabetic vascular disease: from endothelial dysfunction to atherosclerosis.
Topics: Angiotensin-Converting Enzyme Inhibitors; Atherosclerosis; Blood Coagulation Factors; Clofibric Acid | 2005 |
Mode of action of fibrates in the regulation of triglyceride and HDL-cholesterol metabolism.
Topics: Animals; Anticholesteremic Agents; Atherosclerosis; Bezafibrate; Biological Transport; Cholesterol, | 2006 |
[Intensive cholesterol lowering therapy to reduce cardiovascular risk].
Topics: Anticholesteremic Agents; Atorvastatin; Azetidines; Cholesterol, LDL; Clofibric Acid; Coronary Arter | 2006 |
Hypertriglyceridemia: its etiology, effects and treatment.
Topics: Clofibric Acid; Coronary Artery Disease; Diet; Exercise; Humans; Hydroxymethylglutaryl-CoA Reductase | 2007 |
High-density lipoprotein metabolism: potential therapeutic targets.
Topics: Cholesterol, HDL; Cholesterol, LDL; Clofibric Acid; Coronary Artery Disease; Humans; Hydroxymethylgl | 2007 |
Evidence to support aggressive management of high-density lipoprotein cholesterol: implications of recent imaging trials.
Topics: Anticholesteremic Agents; Cholesterol, HDL; Clofibric Acid; Coronary Artery Disease; Disease Progres | 2008 |
Type 2 diabetes mellitus is associated with multiple cardiometabolic risk factors.
Topics: Cardiovascular Diseases; Clofibric Acid; Coronary Artery Disease; Diabetes Complications; Diabetes M | 2007 |
Targeting residual cardiovascular risk: raising high-density lipoprotein cholesterol levels.
Topics: Anticholesteremic Agents; Cholesterol, HDL; Cholesterol, LDL; Clofibric Acid; Coronary Artery Diseas | 2008 |
2 trials available for clofibric acid and Coronary Artery Disease
| Article | Year |
|---|---|
[Changes in serum lipids, plasma fibrinogen and other haemostatic parameters induced by ciprofibrate action in hyperlipidemic patients with and without coronary artery disease].
Topics: Adolescent; Adult; Aged; Cholesterol; Clofibric Acid; Coronary Artery Disease; Female; Fibric Acids; | 2006 |
[Lipanor treatment of atherogenic hyperlipoproteinemia].
Topics: Cholesterol; Clofibric Acid; Coronary Artery Disease; Disease Progression; Drug Administration Sched | 1998 |
8 other studies available for clofibric acid and Coronary Artery Disease
| Article | Year |
|---|---|
Assessment of compliance with lipid guidelines in an academic medical center.
Topics: Academic Medical Centers; American Heart Association; Angioplasty, Balloon, Coronary; Cerebrovascula | 2006 |
[New studies of high dosage statins and fibrates. How is lipid lowering therapy changing? (interview by Dr. med. Dirk Einecke)].
Topics: Anticholesteremic Agents; Cholesterol, LDL; Clofibric Acid; Coronary Artery Disease; Dose-Response R | 2005 |
[IV Brazilian Guideline for Dyslipidemia and Atherosclerosis prevention: Department of Atherosclerosis of Brazilian Society of Cardiology].
Topics: Adult; Age Distribution; Aged; Cholesterol; Clofibric Acid; Coronary Artery Disease; Diet; Female; H | 2007 |
Treating hypertriglyceridemia.
Topics: Adult; Clofibric Acid; Coronary Artery Disease; Diet; Exercise; Heparin; Humans; Hydroxymethylglutar | 2007 |
Treating hypertriglyceridemia.
Topics: Clofibric Acid; Coronary Artery Disease; Diet; Exercise; Humans; Hydroxymethylglutaryl-CoA Reductase | 2007 |
Treating hypertriglyceridemia.
Topics: Clofibric Acid; Coronary Artery Disease; Diet; Exercise; Fatty Acids, Omega-3; Humans; Hydroxymethyl | 2007 |
Interaction of very-low-density, intermediate-density, and low-density lipoproteins with human arterial wall proteoglycans.
Topics: Adult; Aged; Aorta; Apolipoproteins B; Arginine; Chondroitin Sulfates; Clofibric Acid; Coronary Arte | 1997 |
Sialic acid-containing components of lipoproteins influence lipoprotein-proteoglycan interactions.
Topics: Apolipoprotein B-100; Apolipoproteins B; Cholesterol; Chondroitin Sulfate Proteoglycans; Clofibric A | 1999 |